SCHEMBL6340205

SCHEMBL6340205

COc1ccc(Cn2nc(NC(=O)C(NC(=O)OC(C)(C)C)C(C)C)cc2C(=O)O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.44
CA2 P00918 1/20 0.44
CTSS P25774 1/20 0.41
CTSK P43235 1/20 0.41
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
GLS O94925 1/20 0.39
GRN P28799 2/20 0.39
SORT1 Q99523 2/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
HDAC8 Q9BY41 2/20 0.38
PTGER4 P35408 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
PTGER1 P34995 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6407975 0.81 ALDH1A1 (0.43) MEN1KMT2AALDH1A1LMNAPTGER4
SCHEMBL10276787 0.75 CA2 (0.55) CA2CTSSCTSKMEN1KMT2A
SCHEMBL10276786 0.75 CA2 (0.55) CA2CTSSCTSKMEN1KMT2A
SCHEMBL6341603 0.74 ALDH1A1 (0.43) MEN1KMT2AALDH1A1LMNA
SCHEMBL1576775 0.74 FPR2 (0.44) GRNSORT1ALDH1A1LMNAPTGER4
SCHEMBL14397153 0.74 MAPT (0.44) MEN1KMT2AALDH1A1LMNAPTGER4
SCHEMBL8769095 0.73 CA2 (0.71) BRD4CA2CTSSCTSKMEN1
SCHEMBL31510954 0.72 MKNK2 (0.43) PPARGPPARAALDH1A1LMNAPTGDR2
SCHEMBL13387618 0.71 MAPT (0.47) MEN1KMT2AALDH1A1LMNAPTGER4
SCHEMBL6168133 0.71 ALDH1A1 (0.41) MEN1KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050239808-A1 Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur TRANSMIT GESELLSCHAFT FUR TECHNOLOGIETRANSFER MBH (DE) 2005-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239808-A1 Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur PRNP, APP, MAPT BRD4 210/4885CA2 4432/4885CTSS 1899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.